APA (7th ed.) Citation

W, F., CP, M., J, P., M, C., M, H., B, C., . . . KN, B. (2026). Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. HemaSphere, 10(1), e70289. https://doi.org/10.1002/hem3.70289

Chicago Style (17th ed.) Citation

W, Fiskus, et al. "Highly Effective Combination of BRG1/BRM Inhibitor with BET Inhibitor or Decitabine for High-risk MECOM-rearranged AML." HemaSphere 10, no. 1 (2026): e70289. https://doi.org/10.1002/hem3.70289.

MLA (9th ed.) Citation

W, Fiskus, et al. "Highly Effective Combination of BRG1/BRM Inhibitor with BET Inhibitor or Decitabine for High-risk MECOM-rearranged AML." HemaSphere, vol. 10, no. 1, 2026, p. e70289, https://doi.org/10.1002/hem3.70289.